Search

In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study being presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The study will also be published in a corresponding issue of JAMA Oncology.

… Monday, June 5, 2017 In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study being presented at the 2017 annual

Investigators at Memorial Sloan Kettering Cancer Center have found new clues about how metastatic cancer can form long after a primary tumor has been removed.

… Monday, December 1, 2008 Summary Investigators at Memorial Sloan Kettering Cancer Center have found new clues about how metastatic cancer can form long after a primary tumor has been removed. Investigators at Memorial Sloan Kettering Cancer Center have found new clues about how metastatic cancer can

Department of Surgery Chair Jeffrey Drebin discusses MSK’s approach to robotic surgery in response to a recent FDA advisory.

… Friday, March 8, 2019 Summary Jeffrey Drebin, Chair of the Department of Surgery, discusses MSK’s approach to robotic surgery and the importance of having a skilled surgeon for cancer operations. On February 28, the US Food and Drug Administration released a statement cautioning about the use of robotic

May 23, 2007 NEW YORK - The Bright Horizons Foundation for Children, Memorial Sloan Kettering Cancer Center (MSKCC), Abyssinian Development Corporation (ADC), and Community Playthings today cut ribbons to officially open Harlem's first Bright Space center for homeless children at Abyssinian House, a Tier II transitional residence serving the families of Harlem.

… Wednesday, May 23, 2007 The Bright Horizons Foundation for Children, Memorial Sloan Kettering Cancer Center (MSKCC), Abyssinian Development Corporation (ADC), and Community Playthings today cut ribbons to officially open Harlem’s first Bright Space center for homeless children at Abyssinian House, a

Discover how a watch-and-wait approach to treating rectal cancer can help people avoid surgery and preserve normal body functions.

… Tuesday, January 15, 2019 Summary The biggest study of its kind in North America finds a watch-and-wait strategy can have excellent long-term results for some people with rectal cancer. Cancers of the colon and rectum are often grouped together as colorectal cancer because both are part of the large

With the help of machine learning, computational biologists are learning to predict how cancers will evolve.

… Wednesday, June 23, 2021 From amoebas to zebras, all living things evolve. They change over time as pressures from the environment cause individuals with certain traits to become more common in a population while those with other traits become less common. Cancer is no different. Within a growing tumor

Learn about gastrointestinal distress, one of the more common side effects of immunotherapy.

… Thursday, January 31, 2019 Summary One of the most common immunotherapy side effects is gastrointestinal distress. MSK gastroenterologist David Faleck explains why this happens and how to find relief. Chances are that you have heard some buzz about immunotherapy . This type of cancer treatment trains

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024 Breakthrough Prize in Life Sciences.

… Thursday, September 14, 2023 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024  Breakthrough Prize in Life Sciences

Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.

… Saturday, June 4, 2011 Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer , according to a new study. Results from the phase III “OCEANS” trial were presented today by the lead author, Carol Aghajanian, MD , of Memorial Sloan

The FDA has approved an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. The clinical trials resulting in the drug’s approval were led by Dr. Sandra D’Angelo of MSK.

… Friday, August 2, 2024 The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleucel (Tecelra ® , also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called  synovial sarcoma . Afami-cel is the first engineered